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Abstract 
BACKGROUND: Externalizing behaviour problems represent a leading cause for referrals to 
childhood mental health services and have widespread impacts on individuals, families and 
society. Omega-3 deficiency has been implicated with externalizing behaviours. Whether 
increasing omega-3 intake may can alleviate deficiency and thus improve EB in children and 
adolescents warrants investigation. Omega-3 fatty acids have shown to improve behavioural 
outcomes in neurodevelopmental disorders however consensus on whether this extends to a 
typically developing population remains unknown. OBJECTIVE: The objective was to 
evaluate the efficacy of omega-3 supplementation for reducing externalizing 
behaviour problems in typically developing children and adolescents across parent, teacher 
and self-rated measures. DESIGN: Three electronic databases were searched. Randomized 
controlled trials comparing omega-3 to a placebo for behavioural problems were included in 
this review. Risk of bias in included trials was assessed, and the results compared in meta-
analyses. RESULTS: 12 Randomised controlled trials involving 2461 participants were 
included in the review. Standardised mean differences and associated 95% confidence 
intervals, p values, and heterogeneity statistics were calculated. Risk of bias analysis was 
conducted to determine the quality of the randomised controlled trials. No differences were 
observed in oppositional, anti-social and aggressive behaviours compared to control across 
parent, teacher and self-rated measures. No differences were also found for hyperactivity. The 
quality of trials varied. CONCLUSION: The evidence does not conclusively support or refute 
that omega-3 supplementation reduces externalizing behaviour problems in typically 
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 The importance of nutrition and healthy outcomes is well established across the 
literature (Gow & Hibbeln, 2014; Oddy et.al, 2009; Prado & Dewey, 2014). Nutrition is 
especially important during developmental periods with inadequate nutrition being implicated 
with poor developmental outcomes, and in particular behaviour problems… For example, 
Malnutrition at age three has been associated with later externalizing behaviours (Liu et al., 
2004). Omega-3 has been implicated to improve cognitive and behavioural outcomes in 
children with neurodevelopmental disorders, however whether this extends to a typically 
developing population remains unknown. For this reason, the following paper will be 
interested in determining the effectiveness of omega-3 supplementation for reducing 
externalizing behaviour problems in typically developing children and adolescents. 
  
1.1 Externalizing behaviour problems  
Behaviour problems in children are often a normal part of development; all children 
can be defiant and refuse parental directions however some children may experience 
abnormal patterns of challenging behaviours that may be considered outside the norm for 
their age and level of development (Matthys & Lochman, 2017).  Behavioural problems in 
children are most typically categorized into internalizing and externalizing problems. 
Internalizing behaviour problems are difficulties that primarily affect the internal 
psychological environment and may include being withdrawn, anxious, and depressed. In 
contrast, externalizing behaviour’s (EB) can be defined as a grouping of behaviour problems 
that are outwardly expressed and reflect an individual acting negatively on the external 
environment (Eisenburg et al., 2001). EB’s include oppositional, anti-social and aggressive 
behaviour’s (Matthys & Lochman, 2017) and are behavioural domains associated with 
oppositional defiant disorder and conduct disorder; disruptive behaviour disorders recognized 
in the Diagnostic statistical manual of psychiatric disorders (DSM-V; American Psychiatric 
Association, 2013). Hyperactivity is also often referred to as an externalizing behaviour due 
to the co-occurrence and overlapping of symptoms (Matthys & Lochman, 2017), however the 
DSM-V classifies hyperactivity as a behavioural domain associated with attention deficit 
disorder; a neurodevelopmental disorder characterized by different developmental 
trajectories. For this reason, this analysis will consider oppositional, anti-social and 
aggressive behaviour’s as externalizing behaviours and thus the primary outcomes. Due to 
the co-occurrence of hyperactivity with EB, hyperactivity will be included as a secondary 
outcome.  
 
1.1.1 Oppositional behaviours  
 In 2014, 5.1% of Australian children and adolescents had oppositional problem 
  
behaviours which is equivalent to an estimated 204,000 children and adolescents across 
Australia (Lawrence et al., 2015). Oppositional behaviours are noncompliance based 
behaviours when a child is disobedient and resists authority figures. These may include 
arguing with authority figures, refusing to comply with requests or rules and blaming others 
for misbehavior (American Psychiatric Association, 2013). Children with a persisting pattern 
of angry, irritable, argumentative, and vindictive behavior may be diagnosed with 
oppositional defiant disorder and may act as a precursor for more severe behavioural 
disorders like conduct disorder (American Psychiatric Association, 2013; Matthys & 
Lochman, 2017).   
 
1.1.2 Anti-social behaviours (conduct problems) 
Anti-social behaviours (also referred to as conduct problems) can be considered as a 
more severe form of oppositional behaviour and are those which violate basic norms, rights 
and rules.  For example, being defiant, destructive, threatening, lying, cheating, stealing and 
frequent school truancy would be considered antisocial behaviours (Liu, 2004; Matthys & 
Lochman, 2017).  Children who exhibit repetitive and persistent manifestations of these types 
of severe behaviour problems may be diagnosed with conduct and adult anti-social 
personality disorder (Matthys & Lochman, 2017) In 2014, Conduct disorder effected an 
estimated 2.1% of children and adolescents, equating to 83,600 prevalence in the last 12 
months (Lawrence et al., 2015).  
 
1.1.3 Aggressive behaviours 
Aggressive behaviours are those that harm or threaten to harm others, including 
children, adults, and animals and are physical or verbal in nature (American Psychiatric 
Association, 2013). Verbal aggression includes threats or provocation of another individual 
  
with physical aggression involving using physical force to harm another individual, for 
example hitting (Matthys & Lochman, 2017). Aggression is often largely associated with 
anti-social behaviour’s and thus characteristic of CD, however if aggressive behaviours 
persist and deviate beyond normality, an individual may be diagnosed with “intermittent 
explosive disorder,” which is a form of clinical aggression in the DSM-V(American 
Psychiatric Association, 2013) Studies have shown that childhood aggression may act as a 
strong predictor of future adult crime and violence (Liu, 2004) 
 
1.1.4 Hyperactivity  
Hyperactive behaviour is typically characterized by constant activity, being easily distracted, 
impulsiveness, fidgeting, constant moving or wandering (American Psychiatric Association, 
2013).  Whilst hyperactivity is a core characteristic of ADHD, there is a high rate of co-
occurrence of hyperactivity alongside EB problems 
 
1.2 Risk factors  
 The development of behaviour problems is complex and likely involves the 
interplay of social, psychological and biological factors (Baker, Raine, Liu & Jacobson, 
2008). Biological factors may include poor environmental conditions and exposure to 
neurotoxins during pregnancy and development (malnutrition, smoking, drugs) and a genetic 
predisposition to externalizing behavior (Baker, Raine, Liu & Jacobson, 2008). Psychosocial 
risk factors may include but are not limited to high psychosocial stress in early life, poor 
maternal attachment, ineffective parenting, poverty or individuals living in rural or lower 
socioeconomic areas (Liu, 2004; Thijssen, 2016). Gende may also act as moderating factor 
with males more likely to be exhibit externalizing behaviours problems compared to girls 
(Baker, Raine, Liu & Jacobson, 2008; Liu, 2004). Liu (2004) describes a model to explain the 
  
relationship between psychosocial and biological factors and describes the complex 
relationship and interaction between them (see figure 1). In the model, psychosocial risk 
factors can give rise to biological risk factors and vice versa. For example, ineffective 
parenting may act as a psychosocial risk factor which can give rise to biological risk factors 





Figure 1. Development of externalizing behaviours; adapted from Liu (2004) 
 
1.3 Impact of Externalizing Behaviour problems  
EB problems represent a leading cause for referral to child mental health services and 
have widespread impacts on individuals, families and society (Ogundele, 2018). These types 
  
of behaviours generally arise in childhood and have the potential to develop into more severe 
behavioural disorders and substantially impact on a child’s development, educational and 
psychosocial outcomes (Liu, 2004). A study by Kim-cohen and colleagues showed that 
conduct disorder in young children aged five predicted significant behavioural and 
educational difficulties five years later (Kim-Cohen et al., 2009). Childhood EB problems are 
viewed as a public health problem as they are a major risk factor for later juvenile and adult 
delinquency, and violence (Farrington & Loeber, 2000; Sourander et al., 2006). EB have been 
associated with a range of adverse outcomes including poorer educational outcomes, and 
more suspensions and expulsions compared to peers without behaviour problems (Lawrence 
et al, 2015; Liu 2004). Individuals with externalizing behaviour problems during childhood 
also show an increased risk of substance abuse and other mental disorders (Drabick, Gadow, 
& Sprafkin, 2006; Hopfer et al., 2013).  
 
1.3.1 Impact on family/carers  
 Parents and caregivers of children and adolescents with EB problems often 
experience significant burden and distress associated with the caretaking of the child. These 
may include but are not limited to financial burden, family conflict, effect on family social 
life, interruption at work, mental health and physical problems (Meltzer, Ford, Goodman, & 
Vostanis, 2011; Simpson, Cohen, Bloom, & Blumberg, 2009). Children with EB problems 
require more supervision and attention than those without and therefore many parents avoid 
taking these children to public places, relatives and friends due to embarrassment and shame 
resulting from their child’s behaviours. This may result in feelings of isolation and 
resentment towards the child which inevitably can exacerbate EB problems (Meltzer, Ford, 
Goodman, & Vostanis, 2011).  
 
  
1.3.2 Impact on society  
EB problems are a major social and financial burden on society. In 2010, conduct 
disorder was among the fifteen leading causes of the global disease burden among children 
aged 5-19 years. together with ADHD, conduct disorder contributed for 0.8% of the total 
global disability and accounted a total 6.24 million Years lost to Disability(DALY) to the total 
global burden of disease (Erskine, 2014). Furthermore, a study by Scott and colleagues 
(2001) investigated the financial costs of children with behaviour problems for public 
services use where they followed ten year-old children up to the ages of twenty eight. The 
costs for individuals with conduct disorder were ten times higher than children with no 
problems and three and a half times higher than children with milder behavioural problems. 
The fact that externalizing behavior problems can have significant negative long-term 
consequences, highlights the need for preventative programs as well as evidence-based 
intervention options for children and adolescents.  
 
1.4 Current Interventions for behaviour problems  
1.4.1 Psychotherapeutic interventions  
 Psychotherapeutic interventions are currently one of the most common treatment 
options as they have a strong evidence base for reducing EB problems(Sampaio, 2016). A 
meta-analysis found a large effect for psychotherapy for reducing behaviour problems and 
were associated with improvements in parent-child relationship, improved classroom 
behaviour, reduced frequency or aggression outbursts and a reduction in overall 
behaviour outcome scores (Espstein et al., 2015). A later review on parenting 
interventions for behaviour problems showed a similar finding (Tully & Hunt, 2016). 
Despite psychological interventions being an effective treatment option for behaviour 
problems, there are often barriers to accessing therapy, especially for those from regional 
  
areas and lower socioeconomic backgrounds, both where behaviour problems are more 
prevalent (Reiss, 2015). For example, individuals from regional or lower socioeconomic 
areas are less likely and to access therapy and psychological interventions due to financial 
barriers, distance and accessibility of services (Lawrence et al, 2015) 
 
1.4.2 Pharmacological Interventions 
 Pharmaceutical agents are also considered to be an intervention option for 
externalizing behaviours. Epstein and colleagues (2015) reviewed the effect for 
pharmaceutical interventions for EB problems and produced mixed findings. They reviewed 
trials of antipsychotics, ADHD medications, and anti-epileptic medication and were not able 
to find strong effects for treating EB problems in children or adolescents without a 
neurodevelopmental disorder.  Of the trials that did show an effect, generalizability of results 
is limited as many participants also had a co-morbid diagnosis of ADHD and therefore it is 
difficult to determine the true effect for EB problems for those without a diagnosis of ADHD 
(Espstein et al., 2015). An additional review found similar findings (Pringsheim, Hirsch, 
Gardner, & Gorman, 2015).  Furthermore, pharmacological interventions may also be 
associated with adverse side-effects including weight gain (Pringsheim, Lam, Ching, & 
Patten, 2011), involuntary muscle contractions, abnormal electrocardiography readings and 
paranoid tendencies (Espstein et al., 2015; Pringsheim, Hirsch, Gardner, & Gorman, 2015), 
highlighting the need for interventions with a lower side effect profile (Ipser & Stein, 2007)  
 
1.4.3 Dietary supplements   
 Another form of intervention are dietary supplements (DS), which are a type 
of complementary and alternative medicine. DS are often used in adjunction to and/or in 
replacement of traditional intervention options. Many individuals consume DS due to the 
  
importance of good nutrition and associations with healthy outcomes (Gow & Hibbeln, 2014; 
Oddy et.al, 2009).  There has been an increasing use of DS such as fish oil, for mental health 
problems and behavioral management (Sinha and Efron 2005; Barnes et al. 2008). According 
to the Australian Bureau of Statistics, fish oil is the one of the most-commonly taken over the 
counter DS in Australia in children aged between 2-18 (Australian Bureau of Statistics, 
2014). DS are considered more accessible than psychotherapy and individuals may perceive 
them to be safer than pharmacological treatments (Dodge, 2016). However, DS should be 
used with caution as there is insufficient evidence to be considered an evidence-based 
intervention for EB problems (Catala-Lopez et al., 2017). This highlights the need for further 
investigation of the effect of dietary supplementation as an intervention for behaviour 
problems in children and adolescents. 
 
1.5 Importance of nutrition  
 To determine the effect of dietary supplements as an intervention, it is 
important to address the relationship between nutrition status and behavioural outcomes. The 
significance of adequate nutrition in early life is well established (Gow & Hibbeln, 2014; 
Oddy et.al, 2009), with recommended daily intake guidelines existing for a nutritious and 
balanced diet (Australian Dietary Guidelines, 2013). However, contemporary western diets 
often contain large amounts of grains and processed foods which are overloaded with refined 
sugars, sodium and saturated fats and do not contain adequate quantities of important 
nutrients, and in particular omega-3 fatty acids (Prado & Dewey, 2014). This means that 
many individuals are not eating their recommended daily intake and are at risk of being 
malnourished (Gow & Hibbeln, 2014). For example, many Australian children and 
adolescents are reported to consume very low quantities of omega-3 fatty acids and thus may 
not be achieving their recommended intake (see Meyer, 2016). This may have adverse effects 
  
due to the association between inadequate nutrition status during developmental periods and 
adverse developmental outcomes (Oddy et.al, 2009). For example, poor nutrition during 
pregnancy may lead to antisocial behaviours in later life (Neugebauer, Hoek, & Susser, 
1999), Furthermore, research has shown that malnutrition in early life is associated with later 
problematic behaviours (see Liu, Raine, Venables & Mednick, 2004).Given the potential link  
between inadequate nutrition during development and later behaviour problems, raises the 
enquiry as to whether increasing nutrition intake, and of particular interest omega-3 can help 
to improve EB problems in children.  
 
1.6 Omega fatty acids  
 Omega fatty acids are essential dietary fats necessary for typical development 
and functioning of the brain and immune system. They cannot be made by the body and must 
be consumed through diet or supplementation (Gow & Hibbeln, 2014). There are various 
types of essential fatty acids and they are classified by the position of their double carbons 
bonds which determines whether the molecule is an omega-3 fatty acid or omega-6 fatty acid. 
For example, the first double bond of omega-3 fatty acids are located at the third carbon atom 
and include docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and α-linolenic acid 
(ALA). Linoleic acid (LA) and arachidonic acid (AA) are omega-6 fatty acids and are located 
at the sixth carbon atom (See figure 2;Schuchardt, Huss, Stauss-Grabo & Hahn, 2010). 
Primary dietary sources of DHA and EPA include cold water fatty fish, milk and eggs 




Figure 2:  Structure of Omega-3 and Omega-6 fatty acids. Taken from (Schuchardt, 
Huss, Stauss-Grabo & Hahn, 2010, p. 2).  
Omgea-3’s are important for a range of metabolic functions. It is estimated that about 
sixty percent of the dry weight of an adult brain is comprised of lipids, making up eighty 
percent of nerve cells (Benton & Europe, 2008; Gow & Hibbeln, 2014). Omega-3’s are major 
structural components in cell membranes in the brain and body. They act by helping to 
preserve and support the membrane by maintaining its fluidity and the activity of proteins 
contained within these membranes (enzymes, receptors, transporters, voltage-gated ion 
channels, etc; Choy & Raine 2018).  They are also associated with many important 
neurological functions including neurotransmission, stimulating neurite outgrowth, and 
enhancing synaptic functioning and dendritic branching, gene expression, and myelination 
(Gow & Hibbeln, 2014; Hibbeln, Ferguson, & Blasbalg, 2006). 
 
1.7 Omega-3 and brain development  
  
The mechanisms of action by which inadequate omega-3 intake during development 
may be implicated with EB problems is important to determine the potential efficacy of 
omega-3 supplementation. Omega-3’s play important roles during developmental periods; 
Infancy, childhood and adolescence are critical periods of development where the brain 
undergoes substantial structural and functional changes. Omega-3 is said to contribute to the 
establishment of connections between the frontal lobe regions in the brain that are responsible 
for important functions including attention, executive function and decision making 
(McNamara, Vannest & Valentine, 2015). Research has shown that structural and functional 
deficits in the prefrontal cortex are associated with externalizing behavior (Yang & Raine, 
2009). Thus, inadequate intake of omega-3 during development may lead to reduced 
connectivity between these regions and increased risk of EB (Hibbeln et al., 2006). Humans 
studies on infants have reported that infants born preterm have reduced levels of DHA which 
has been associated with significant reductions in volume of various regions of the brain and 
reduced connectivity between them, which may be mitigated by postnatal high-dose DHA 
supplementation.  Moreover, increases in DHA during development has been associated with 
active periods of a range of neurobiological functions including synaptogenesis, grey matter 
expansion and neurogenesis where new brain cells are formed (see Gow & Hibbeln, 2014; 
Hibbeln, Nieminen, Blasbalg, Riggs & Lands 2006). Omgea-3 deficiency may impair many 
these functions leading to disruption of neuronal pathways that regulate behaviour which may 
result in a residual predisposition toward aggressive and atypical behaviours (Hibbeln et al., 
2006; McNamara, Vannest & Valentine, 2015). For example, animal studies have shown that 
reduced levels of omega-3’s during early development leads to dysregulated neurotransmitter 
function which may be associated with later behaviour problems (McNamara, Vannest & 
Valentine, 2015).  However, whether this effect extends to humans remains unclear. 
Nonetheless, omega-3 supplementation is suggested to reduce externalizing behaviours 
  
through improved regulation of neurotransmitters and hormones, specifically serotonin and 
dopamine in the frontal cortex (Gow & Hibbeln, 2014). The potential role for omega-3 
intervention during childhood and adolescence could be deemed plausible; research suggests 
that although by six years of age the brain is about 95% of its final size, expansion of the grey 
matter, especially in frontal regions, continues to increase throughout puberty and 
adolescence (Benton, 2008). Since omega-3 plays important roles in grey matter expansion 
and the development of the frontal cortex, omega-3 intervention during childhood and 
adolescence may be effective. Given the association between inadequate omega-3 during 
development and EB problems, whether an intervention of omega-3 during development 
periods can correct deficits and thus risk for behaviour problems warrants further 
investigation. 
 
1.8 Omega-3 and neurodevelopmental disorders  
 Numerous studies have demonstrated a connection between omega-3 and various 
neurodevelopmental disorders due to the association between lower levels of omega-3 and 
individuals with psychiatric symptoms compared to individuals without (Hibben, Hawkey & 
Nigg, 2014). Whether these irregularities are due to low dietary intake of omega-3 or 
individuals experience abnormality in omega-3 metabolism is difficult to determine. For this 
reason and the growing awareness of the role of nutrition in neural development, research has 
been focused on determining whether omega-3 supplementation can rectify developmental 
deficits and thus related outcomes in these populations. Various randomized controlled trials 
have investigated this effect in individuals with ADHD (Gustafsson et al., 2010; Hirayama, 
Hamazaki & Terasawa, 2004; Johnson, Ostlund, Fransson, Kadesjo & Gillberg, 2009; Raz, 
Carasso & Yehuda, 2009; Voigt et al., 2001) Gustafsson and colleagues showed improvement 
in behaviour problems in children with ADHD after 15-week EPA treatment. Johnson et al., 
  
also showed positive findings for reducing behaviour problems (2009). However, Voigt and 
colleagues (2001) did not reproduce such an effect. A Cochrane review also reported mixed 
findings (Gillies, Sinn, Lad, Leach, & Ross, 2012).  This effect has been investigated in 
individual’s with autism spectrum disorders (ASD) with findings also showing mixed results 
(see Cheng et al., 2017; Hovarth, Łukasik, & Szajewska, 2017).   
 
1.9 Omega-3 and typically developing populations 
 Despite research into the effectiveness of omega-3 supplementation for 
reducing behavioural outcomes in individuals with neurodevelopmental disorders, little is 
known about whether this effect extends to a typically developing population (TDP). Of the 
research that has been conducted, results have been mixed. For example, Richardson and 
colleagues conducted a well-known randomized controlled trial and found that n-3 
supplementation reduced parent-rated externalizing behavior problems significantly 
compared to placebo (Richardson, Burton, Sewell, Spreckelsen & Montgomery, 2012) 
however this effect was not found for teacher reported data. Montgomery and colleagues 
attempted to replicate this effect, however no significant results were found (Montgomery, 
Spreckelsen, Burton, Burton, & Richardson, 2018). Whilst some reviews have focused on EB 
problems in a TDP (Choy & Raine 2018; Kuratk, Barrett, Nelson & Salem, 2013) there is yet 
to be a review that collates these studies into a meta-analysis to determine whether there is an 
effect. Gajos & Beaver, (2016) conducted a meta-analysis on omega-3 supplementation for 
aggression, however they included both TDP and individuals diagnosed with ADHD and 
other psychiatric disorders, as well as both children, adolescents and adults. This makes it 
difficult to determine the true effect of omega-3 in children and adolescents of a TDP. They 
also looked at the construct of aggression as a whole, combining EB domains (aggression, 
oppositional and antisocial/conduct behaviour) rather than looking at individual constructs. 
  
Whilst these constructs are similar and belong to a similar domain of behavioural problems, 
they are also distinct constructs and do not always present synonymously. For example, a 
child may display oppositional behaviours and not show any forms of aggression or anti-
social behaviour (Matthys & Lochman, 2017). It is therefore difficult to determine whether 
these behaviour domains respond differentially to supplementation. Furthermore, they 
combined teacher, parent rated and self-rated outcomes. Due to the potential effects that the 
rater may have on the outcome, it is important to examine EB behaviour’s separately due to 
differences in perspectives of ratings. For example, a parent may have a stronger insight into 
their child’s behavioural problems and may be more sensitive to small changes compared to a 
teacher’s ratings (Kirby, Woodward, & Jackson, 2010). 
 
1.10 Importance of this review  
Given that EB problems represent a leading cause for referrals to childhood mental 
health services and have widespread impacts on individuals, families and society. In addition 
to the possible relationship between omega-3 deficiency during developmental periods and 
EB, highlights the need to determine whether omega-3 supplementation can alleviate 
deficiency and thus improve EB in children and adolescents. Because omega-3 
supplementation is a highly accessible intervention, an analysis of randomized controlled 
trials is needed to establish the evidence base of omega-3 supplementation.  Whilst there have 
been numerous studies reviewing the efficacy of omega-3 supplementation for reducing 
behaviour problems in children and adolescents with neurodevelopmental disorders, there is 
limited evidence on whether this effect extends to children and adolescents from a typically 
developing population. Increasingly, RCTs are being conducted to examine whether there is a 
benefit in a typically developing population however these have shown mixed results. In 
addition, there is yet to be a review within this area that collates these studies into a meta-
  
analysis to determine whether there is an effect on EB problems. Meta-analyses are 
considered the highest level of evidence and are important to determine the evidence base of 
an intervention (Haidich, 2010).  Therefore, this analysis sought to expand on previous 
research (Gajos & Beaver, 2016) and recognize the need for a comprehensive systematic 
review of RCTs for which results are quantified in a meta-analysis is conducted according to 
the Cochrane handbook (Higgins & Green, 2011). This review is needed as it will examine 
randomized controlled trials to determine the evidence base of omega-3 supplementation for 
reducing externalizing behavioural problems (oppositional, conduct and aggressive 
behaviours) across various respondents (parent, teacher and self-rated) in TD children and 
adolescents, which to the best of our knowledge has not been done. 
 
1.11 Aims 
The current review will use meta-analytic techniques to determine the effectiveness 
of omega-3 supplementation for reducing externalizing behaviours in typically developing 
children and adolescents. It was broadly hypothesized that there would be significant 
differences in externalizing behaviour scores across respondents (parent, teacher and self-
rated) and externalizing behavioural domains (oppositional, anti-social and aggressive 
behaviour) in children and adolescents receiving omega-3 supplementation compared to 
placebo.  
 
The following are the review aims:   
1. Determine whether there is a significant difference in primary outcomes 
(oppositional, anti-social and aggressive behaviour) across parent, teacher and 
self-rated in groups receiving omega-3 supplementation compared to placebo 
  
2. Determine whether there is a significant difference in secondary outcomes 
(Hyperactivity) in groups receiving omega-3 supplementation compared to 
placebo 
3. Examine risk of bias of included trials and the degree of study heterogeneity. 
2. Method 
2.1 Search strategy  
Eligible studies that examined omega -3 supplementation for behaviour problems 
were sourced using a systematic search strategy from the databases in July 2018 shown in 
table 1. Search was undertaken with no date restrictions. A manual search of the reference 
lists of eligible studies and reviews was also conducted to determine additional studies that 
may not have been captured on the literature search. 
Table 1: 
Databases searched  
Database Date searched  
EMBASE (Ovid)  23/7/2018 
PubMed  23/7/2018 
PsycINFO   23/7/2018 
Cochrane 24/07/2018 
Eu clinical trials register  24/07/2018 
Clinical trials.gov  24/07/2018 
Australian New Zealand Clinical Trial Registry 24/07/2018 
Australian Clinical Trials 24/07/2018 
 
Search terms included a combination of keywords for the search strategy such as “omega-3” 
“Behaviour” and “Randomized controlled trials” figure 3 shows example of PubMed search 
  
strategy (see appendix 1 for full list of search terms for each database). A research librarian 
assisted with the development and reviewing of the search strategy to ensure all relevant 
articles were found. The reference lists of reviews and eligible articles identified by the 
search were also screened. The search was last conducted in July 2018, email alert was set up 










Figure 3: PubMed Search terms  
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 Studies were included in the current meta-analysis if they met the following 
criteria: Were (A) randomised controlled trials comparing the efficacy of omega-3 
supplementation compared to a placebo for externalizing behaviours problems which could 
include any form of omega-3 supplementation (DHA, EPA and ALA) with or without 
additional vitamins. Participants were included if they were (B) typically developing school 
aged children and adolescents aged between 4-18. Studies included used (C) 
psychometrically validated measures of externalizing behaviour problems and had to (D) 
provide quantitative end point data (i.e. group means and SD’s, SE’s etc) and be (E) 
published in English. Studies were excluded if they: Were (A) not a randomized controlled 
trial (i.e observations studies, case studies), (B) Participants had a diagnosis or suspected 
diagnosis (including high scores on a diagnostic measure) of ADHD, Autism, intellectual 
disability or a severe psychiatric disorder (psychosis, schizophrenia or bipolar), had been 
taking omega-3 supplements or medication that can influence behaviour, prior to the trial.    
 
2.3 Screening of Studies  
Screening of studies was conducted using Covidence systematic review software 
(Veritas Health Innovation, Melbourne, Australia) a program designed to screen searches in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta- analysis 
(PRISMA) guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009).  
 
2.4 Data extraction  
In alignment with the PRISMA guidelines (Moher, Liberati, Tetzlaff, & Altman, 
2009), data was systematically collected using a data extraction form that had been adapted 
from the Cochrane Collaboration pregnancy group (see appendix 2).  Extracted data included 
study characteristics (country, setting, measures used), risk of bias analysis, participant 
  
demographics (e.g. mean age, gender and socioeconomic status) and statistical data (e.g. 
means and SDs for measures of behaviour problems). Intention to treat data was used where 
available, a method recommended for dealing with missing data in RCTs (see Gupta, 2011). 
End point data was also used as recommended by the Cochrane handbook (Higgins & Green, 
2011). As a meta-analysis is based on assumptions of normality, continuous data was checked 
for skewness prior to being included in the meta-analysis (Higgins & Green, 2011) which was 
conducted by reading the results of the trials.  
 
2.5 Risk of bias analysis  
 Risk of bias analysis was undertaken using the method recommended by the 
Cochrane collaboration for assessing the validity of randomized controlled trials (Higgins & 
Green, 2011). Trials were assessed on the following criteria (A) the adequacy of sequence 
generation (selection bias); (B) allocation concealment(selection bias); (C) the blinding of 
participants and personnel(performance bias); (D) the blinding of outcome 
assessors(detection bias); E) incomplete outcome data(attrition bias); and (F) selective 
outcome reporting(reporting bias) and other potential sources of bias. Trials was assessed 
according to 'low risk of bias', 'high risk of bias' or 'unclear risk of bias' as per the Cochrane 
handbook (Higgins & Green, 2011).   
 
2.6 Data Preparation  
 Prior to data analysis, recalculation was required for two studies. Hamazaki 
reported two subscales of aggression (verbal and physical). These scores were averaged to 
provide an overall aggression score (see Cochrane handbook on this method; Higgins & 
Green, 2011). Dean (2010) reported standard error and mean which was converted to SD 
  
using Review Manager calculator (Version 5.2.3, ©2014 Cochrane Collaboration, 
Copenhagen).   
 
2.7 Statistical Analysis and Interpretation 
 The standardized mean difference (SMD) was used as the summary statistic 
for the meta-analysis which is calculated by pooling the standardized mean behavioural 
reduction of each study outcome using Review Manager 5.3 (Version 5.3, ©2014 Cochrane 
Collaboration, Copenhagen).  SMD was used over weighted mean differences as it allows the 
assessment of the same outcome from different psychometric scales (Higgins & Green, 
2011). In the SMD approach, the standard deviations are used to standardize the mean 
differences to a single scale, as well as the computation of study weights (Higgins & Green, 
2011). A random effects model was be used which is consistent with other meta-analysis on 
omega-3 trials (see Gillies et al, 2012). Unlike the fixed effects model, the random effects 
model assumes that the true effect is related but not identical across studies because of 
sampling and methodological differences (Borenstein, Hedges, Higgins, & Rothstein, 2009; 
Higgins, Thompson, Deeks, and Altman, 2003). The random effects model is based on the 
inverse-variance approach, where adjustments to the study weights are made according to the 
extent of the variation (or heterogeneity; Higgins & Green, 2011). Heterogeneity is the 
variability in the intervention effects and manifests when observed intervention effects are 
more different from each other than what would be expected due to random error. 
Heterogeneity statistics, Cochran’s Q and I2 index, will be calculated for analysis’s that 
include two or more RCT’s. Calculation of the I2 index is based on the following formula 
provided by Higgins, Thompson, Deeks, and Altman (2003):   
  
  
Q is Cochran’s (chi-square) heterogeneity statistic and df is the degrees of freedom. 
This describes the variability in effect estimates due to heterogeneity.  I2 quantifies 
inconsistency across studies and is expressed as a percentage. Interpretation of heterogeneity 
is described in table 2 below.  
Table 2: Heterogeneity interpretation 
I2 Percentage  Interpretation of heterogeneity  
 0% to 40%: Low heterogeneity 
30% to 60%:* Moderate heterogeneity 
50% to 90%:* Substantial heterogeneity*; 
75% to 100%:* Considerable heterogeneity*. 
Note: *The importance of the observed value of I2 depends on (a) the magnitude and 
direction of effects and (B) strength of evidence for heterogeneity (e.g. P value from the chi-
squared test, or a confidence interval for I2) (Higgins & Green, 2011). 
 
In order to determine the precision of each summary statistic, 95% confidence 
intervals (CIs) was calculated for both individual SMD and the combined SMD of trials.  CIs 
that do not include the value of zero are said to be statistically significant (Thompson, 2007). 
Rosenthal, (1979) and Orwin (1983) suggest assessing the potential for publication bias 
influencing the results of a meta-analysis by calculating the ‘fail-safe N’. However, the 
Cochrane Collaboration advises against the use of ‘fail-safe N’ for reviews following the 
Cochrane handbook and therefore this statistic will not be used in this analysis (Higgins & 
Green, 2011). Post outcome standard deviations and means from scores from standardized 
measures will be used to determine the SMD. If a RCT provided multiple behavioural 
subdomain for one behavioural outcome (e.g. multiple subscale scores for a single outcome) 
a mean effect was calculated for that study. Differences across groups was considered 
significant if (a) the standardized mean difference represents a small 0.3 to large effect 0.8 
(Cohen 1988), consistent with other meta-analysis on omega-3 trials (see Gillies et al, 2012), 
  
and (b) the associated 95% CI does not span zero. Heterogeneity and risk of bias will also be 




3.1 Study selection  
11 Randomized controlled trials were included in this review.  The initial database 
search produced 358 articles and after removal of duplicates, this number was reduced to 311. 
Title and abstracts were screened for relevance using inclusion and exclusion criteria which 
resulted in 31 studies. The full-text of these studies were screened against eligibility criteria 
and excluded with reasons provided (see appendix 3). Thirteen of these studies included 
participants from clinical populations, eight of these studies were not RCT’s, three of these 
studies did not include behavioural outcomes and two were literature reviews. Furthermore, 
four studies did not contain outcome data and were not included; Two of which were pilot 
studies or protocol’s (Damsguard, 2016; Sinn, 2011), one study was an ongoing study which 
was confirmed by contacting the author (Fung, 2018) and one of these studies did not contain 
post outcome data (Parletta, 2014) and therefore the main author was contacted to see if data 
was available. However, data was not able to be retrieved as teacher’s who completed 
baseline questionnaires left the school and therefore for this reason was this trial was 
excluded from the review. This resulted in 11 eligible trials to be included in this review 
(refer to Figure … for a summary of the search process).  During data extraction, two of these 
studies were identified to not be able to include in the meta-analysis and therefore were 
instead included in the qualitative review (Itomura, 2005; Raine, 2015). This resulted in nine 




Figure 4: PRISMA flowchart of study selection process  
  
3.2 Study characteristics  
See table 3 for characteristics of trials included in this review. Majority of trials 
reported a double-blind randomization design, with the exception of one study which 
reported a single blind design where participants were aware of what intervention they are 
receiving (Raine, 2016). Most of trials were parallel design, with two as cross-over (Dean, 
2010; Kirby, 2010) and one factorial design (Smuts, 2015). Most studies utilised intention to 
treat analysis(refs) and three used per protocol data (Itomura, 2005; Tamman, 2016; Smuts, 
2015). Trials were published in peer-reviewed journals, with publication dates ranging from 
2005 to 2018. Sample sizes of trials ranged from 21 to 450. All of the studies relied on 
psychological measures for the assessment of behavioural problems including the Child 
Behavioural Checklist (CBCL) (Raine, 2015; Raine, 2016) subscales of the Conners Parent 
rating scales (Montgomery, 2018; Richardson, 2012) and Conners Teacher Rating Scales 
(Montgomery, 2018; Richardson, 2005; Richardson, 2012, Tamman, 2016; Smuts, 2015) the 
Hostility-aggression questionnaire for children (HAQ-C) (Hamazaki, 2008; Itomura, 2005) 
and the Strengths and difficulties questionnaire (Dean, 2010; Kirby, 2010). Many of these 
measures show strong psychometric properties (Achenbach, 1978, Buss and Perry, 1992, 
Conners, Sitarenios, Parker & Epstein, 1998; Goodman, 2001). Majority of studies reported 
means and SD’s allowing calculating the calculation of effect sizes. One trial reported 
standard error (Dean, 2010). Raine (2016) reported unadjusted mean and 95% confidence 
intervals which could not be used and therefore the lead author was emailed to determine if 
additional data was available to be used in the meta-analysis. One study (Itomura, 2005) 
reported data that was skewed and therefore was excluded from the meta-analysis. Most trials 
were conducted in high-income countries including the United Kingdom, USA, Australia and 
Japan, and three trials were conducted in lower income countries; Indonesia, South Africa 
and Mauritius.  
  
Table 3:  Study Characteristics 
Study  Setting  Study 
design 
N Age  Duration  Outcome measurement  Outcome of 
interest 
Type of supplement  Type of 
placebo 
Kirby 2010 UK  Cross-over 450  8-10 4 months   Strengths and Difficulties 





Fish oil capsule  
DHA – 200mg 
EPA – 28mg 
Italian Olive 
Oil  
Richardson 2012 UK  Parallel 362 7-9 4 months   Conners rating scale – 
Teacher report   
Oppositional and 
hyperactive 
behaviour   
Algal oil capsule 





Parallel 233 9-12 3 months   Hostility-Aggression 





Fish oil Capsule  
DHA 650mg  
EPA 100mg 
Soybean Oil  
Itomura 2005 Japan  Parallel 166 9-12 3 months   Hostility-Aggression 









fortified food  
Montgomery 
2018 
UK  Parallel 376 7-9 4 months   Conners rating scale – 




Algal oil capsule 





Parallel 200 8-16 6 months  Child behaviour checklist - 
Parent and youth self-report  
Rule breaking and 
aggression 

















USA  Cross over 290 11-
12 
3 months Child behaviour checklist - 
Parent and youth self-report 
Rule breaking and 
aggression 
Fruit juice with 










Dean 2010 AUS Prospective  21 6-17 3 months   Strengths and Difficulties 




Fish oil Capsule  
DHA 2000mg 
EPA 400mg 
Olive oil  
10mg fish oil  
Tamman 2016 UK  Parallel 196 13-
16 





Fish oil capsule  
DHA 116mg  
EPA 165mg  
Sunflower 
oil, olive oil 
10mg fish oil 





Fish oil 80% 
Primrose oil 20% 
Capsule  
Olive oil  
Smuts 2015 South 
Africa 
Factorial  20 6-11 8.5 
months  












 The trials involved a total of 2461 participants. Participants age ranged from 4-17 
years. Majority of the trials included participants from a typically developing school aged 
population. However, some studies did not include exclusion criteria and therefore it is 
difficult to determine whether these children would meet the criteria of a neurodevelopmental 
disorder such as ADHD or autism (Hamazaki, 2008; Itomura, 2005). Two studies included 
participants who were in the lower percentile in reading (Richardson, 2012; Montgomery, 
2018), one study included participants with a developmental co-ordination disorder 
(Richardson, 2005) and one study included participants who had a diagnosis of a behaviour 
disorder such as CD or ODD (Dean, 2010).  
 
3.4 Intervention 
 All the included trials used oral based intervention of omega-3 including functional 
foods, fortified juice or capsules. Majority of the studies used fish oil as the primary source of 
omega-3, with one trial sourcing from algal oil and primrose oil (Richardson, 2005). The 
types of omega-3 and quantities varied. For example, doses of omega-3 varied from 184mg/d 
to 2400mg/d with interventions including both EPA and DHA in majority of studies and two 
studies using DHA alone (Richardson, 2012; Montgomery, 2018). Three studies also included 
ALA (Raine, 2015; Raine, 2016; Richardson, 2005). Four of the included studies included 
additional vitamins as part of the intervention, these included Vitamin D (Raine 2015; 2016), 
a combination multivitamin (Tamman 2016), and vitamin E (Richardson 2005). All studies 
included a control group however varied with the type of placebo used. For example, placebo 
types included soybean oil used in four studies (Itomura, 2005; Hamazaki, 2008; 
Montgomery, 2018; Richardson, 2012) corn oil (Montgomery, 2018; Richardson, 2012), 
sunflour oil (Tamman, 2016) juice with multivitamin (Raine, 2015; Raine, 2016), Olive oil 
  
(Dean, 2010; Richardson, 2005) and medium chain TAG (Smuts, 2016). The length of 
intervention varied from 3 months to 8.5 months. Whilst some studies reported follow up 
data, these were not included as part of the meta-analysis.   
 
3.5 Risk of bias 
Risk of bias was assessed using the Cochrane Collaboration’s tool (Higgins 2011).  A 
summary of the risk of bias associated with each trial is shown in figure 3. All trials reported 
adequate randomization methods. However, some trials lacked clarity on allocation 
concealment methods (Hamazaki 2010; Itomura, 2005; Raine, 2015 Smuts, 2015) or reported 
high risk methods including allocating participants to the next consecutive number which 
allows researchers to predict allocation (Dean 2010), increasing the risk of selection bias. 
Most of the trials adequately blinded participants and assessors to the treatment allocation 
and outcome assessment and therefore were rated as low risk. However, two studies were 
rated as high risk due to quality of blinding methods (Hamazaki, 2005; Itomura, 2005) and 
one study was rated high due to being a single blind open trial, where participants were aware 
what intervention they were receiving.  One trial was rated as unclear as they did not address 
blinding methods (Smuts, 2015). Most trials used matching interventions and placebos and 
because parent and teacher rated measures were used, were rated as a low risk bias for 
blinding of outcome assessment; two studies were rated as high risk as they did not 
adequately match the intervention and placebo (Raine, 2016; Itomura, 2005) and two study 
did not adequately describe methods which was classified as unclear risk for blinding of 
outcome assessment (Hamazaki, 2005; Smuts, 2015). Attrition rates varied between studies, 
some studies reported attrition rates that would be considered high risk (>20%, Kirby, 2010; 
Richardson, 2012; Montgomery, 2018) as they utilized intention to treat analysis; studies 
were thus rated as low risk with the exception of one study which reported attrition rates of 
  
85-90% which was rated as high risk (Richardson, 2005). Two remaining studies were rated 
as high risk of attrition bias; Smuts 2015 did not report baseline data and therefore it was 
difficult to determine attrition rates and another study reported high rates of attrition (Kirby, 
2010). All trials reported outcomes that was described in the method or protocol, except for 
when there were issues with missing data.  Other risk of bias was determined to be unclear 
for most trials except for one study which was substantially underpowered (Dean, 2010).   
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Discussion 
 Various systematic reviews and meta-analyses have examined the efficacy of 
omega-3 consumption for improving symptoms in neurodevelopmental disorders, but no studies 
to date have explicitly examined this effect for reducing externalizing behaviour problems in a 
typically developing (TD) population using meta-analytic techniques. The purpose of the 
current meta-analysis was to examine RCTs to determine the effectiveness of omega-3 
supplementation for reducing externalizing behaviour, and in particular individual externalizing 
behavioural domains in TD children and adolescents. Overall the results from this meta-analysis 
show that there is limited evidence that Omega-3 fatty acid supplementation provides a benefit 
for externalizing behavioural problems in children and adolescents across each respondent type 
(parent, teacher and self-rated) and behavioural domains (oppositional behaviour, conduct 
problems, aggression). Although some individual RCT’s show positive findings for reducing 
externalizing behaviours in children and adolescents (Richardson, 2005; Richardson, 2012; 
Kirby, 2010) combined with other studies, this effect was not able to be found. There was also no 
indication of a beneficial effect of omega-3 on hyperactivity, a behavioural domain typically 
associated with ADHD.  These results are consistent with the literature on omega-3 
supplementation which have shown mixed results.  For example, A meta-analysis by Bloch, 
(2011) found a small but significant reduction in ADHD symptoms with omega-3 
supplementation. However, Gillies and colleagues (2012) found limited evidence for the 
effectiveness of omega-3 supplementation for behaviour problems in children and adolescents 
with ADHD. This is also been found for meta-analysis on omega-3 supplementation in 
pregnancy for cognitive outcomes (Gould, Smithers, & Makrides, 2013). Risk of bias analysis 
reported variation in the validity across trials, highlighting the differences across methodologies.    
[SHORTENED TITLE UP TO 50 CHARACTERS] 46 
 The findings reported in the meta-analysis could be the result of several factors. 
For example, many of the trials included had relatively small sample sizes and thus may not be 
adequately powered. Bloch and Qawasmi highlighted that in order to have sufficient power (β = 
80%, 2-tailed α = 0.05) to detect a significant difference (effect size of 0.31), RCTs of omega-3 
interventions compared to placebo would require a sample size around 330 children (2011). Of 
the trials included in this review only three of the studies would be considered adequately 
powered according to this evaluation (Kirby, 2010; Montgomery, 2018 & Richardson, 2012). 
Bloch and Qawasmi suggest that the many of the sample sizes in RCTs to date are therefore 
underpowered and may account for some of the inconsistent findings in omega-3 research 
making them more susceptible to methodological flaws (2011). Another important factor to 
consider is that majority of trials utilised ITT analysis. Whilst this is typically viewed as an 
advantageous approach in RCTs, it may also underestimate the treatment effects (Hernan & 
Hernandez-Díaz, 2012).  
 Furthermore, inter-individual variability may play a role in determining the 
effectiveness of omega-3. Ghasemifard and colleagues highlight the importance of not using a 
fixed dose for individuals in omega-3 trials and instead adjusting the dosage to suit the 
individual. For example, the omega-3 dosage in many trials are not weight adjusted and therefore 
children and adolescents who weigh more may require higher dosages compared to those who 
weigh less for an effect to be determined (Ghasemifard, Turchini & Sinclair, 2014). A study on 
omega-3 and cardiovascular health highlights this inter-individual variability where 69 
individuals ingested 1g per day of EPA and DHA for 3 months reporting a highly variable 
response to supplementation. It was shown that omega-3 blood levels were elevated 4-fold in 
some individuals while other participants showed a limited response (Von, 2010). Interestingly, a 
[SHORTENED TITLE UP TO 50 CHARACTERS] 47 
study that administered weight-adjusted doses of DHA/EPA in a sample of children, found 
significant increases in Omega-3 blood levels as well as a significant improvement in motor 
skills (Beblo, Reinhardt, Demmelmair, Muntau, & Koletzko, 2007). Whether this effect was the 
result of weight adjusted doses warrants further investigation.  
 The optimum dosage of EPA and DHA for an effect to be determined is also 
unknown, especially within a typically developing population where smaller changes may be 
expected (Kuratko, Barrett, Nelson, & Salem, 2013). In the trials in this analysis, dosage ranged 
from 184mg per day to 2400mg, with EPA ranging from 28mg to 558mg p/day and DHA 116mg 
to 2000mg p/day across trials. Because the optimum dosage of omega-3 is unknown, the dosage 
in the active treatment in some trials may not be at an optimum level to have an effect on 
behaviour outcomes (Kirby, Woodward, & Jackson, 2010). This substantial variation between 
dosages could contribute for the variability in results in omega-3 supplementation trials and thus 
the lack of effect in this analysis (Frensham, Bryan & Parletta, 2012; Gajos & Beaver, 2016) 
Moreover, the variation in the length of supplementation may also play a role. Trials ranged from 
3months to 8.5 months in this analysis. Early research suggests that it takes approximately 3 
months for omega-3 levels to see effects from supplementation due to the slow turnover in the 
neuronal membrane (Kirby, Woodward & Jackson, 2010). However, this was based on rat studies 
which therefore is difficult to determine the time it takes for humans to build up omega-3 levels 
for an effect to be seen remains unknown. Furthermore, it is suggested that the turnover of 
omega-3’s in the brain in children and adolescents is slower after 2 years of age and therefore 
longer periods of supplementation may be required to alter the omega-3 content of the CNS and 
thus see related effects (Ryan & Nelson, 2008). Future research is needed to determine the 
optimal dose and length of omega-3 supplementation needed to benefit a various psychological 
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outcomes across different age groups. There is also large variation in the makeup for the 
supplements with some trials containing purely DHA (Montgomery, 2018; Richardson, 2012) 
with remaining trials including DHA and EPA and some with ALA combined (Raine, 2015, 
Raine, 2016, Richardson, 2005) which could contribute to inconsistent results due to the 
differential effects of EPA and DHA (Dyall, 2015).  Whilst a previous meta-analysis on 
aggression was able to find consistent results even when different types of omega-3 fatty acids 
were administered/assessed (Gajos & Beaver, 2016), Bloch and Qawasmi (2011) found that 
higher doses of EPA compared to ALA and DHA were significantly but modestly correlated with 
omega-3 efficacy in the treatment of ADHD.  It is unclear why EPA improved ADHD symptoms 
while supplementation with DHA did not to the same degree. DHA is considered the most 
important omega-3 in the brain, and as a result has been the most studied, however emerging 
research is starting to determine the importance of EPA. Research from adult studies suggests 
EPA may be more effective in reducing a various symptom’s in neurodevelopmental and 
psychiatric disorders compared to DHA (Gesch, Hammond, Hampson, Eves & Crowder, 2002). 
In this analysis, all trials that included EPA also included DHA as an intervention and therefore 
comparative analysis could not be done. Future research could be focused on comparing the 
efficacy of EPA to DHA in typically developing populations to determine whether it can improve 
behavioural problems.  It is also important to note that many of the placebos used in the trials in 
this review used supplements which are made of other types of oil including olive, soybean, 
cornflour and sunflour oil which may be considered bioactive (…) For example, cornflour and 
sunflour oil may provide additional LA,  soybean may provide ALA, or monounsaturated fatty 
acids and polyphenols from olive oil. (Dyall, 2011).  
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 Despite substantial methodological inconsistencies, the effect observed in omega-
3 trials in neurodevelopmental and psychiatric disorders trials, may not extend to a typically 
developing population. Much of the support for the efficacy of omega-3 supplementation relies 
on the notion that individuals with neurodevelopmental and psychiatric disorders have 
significantly lower omega-3 levels than those from a typically developing population. Whilst it is 
not known whether irregularities are due to low dietary intake of omega-3’s or if these 
populations experience abnormality in PUFA metabolism, it highlights the fact that individuals in 
typically developing populations may not be deficit in omega-3 and therefore may account for 
the lack of effect from supplementation.  
 
4.1 Clinical implications 
 Whilst there was no effect found for omega-3 supplementation for reducing 
externalizing behaviour problems in this analysis, it does highlight and draw attention to the lack 
of consistency across omega-3 RCT’s research which may assist in formulating more consistent 
methodologies to determine whether there is an effect. Dyall, argues that until there is universal 
clarity in the reporting of techniques and consistency’s in methodology in omega-3 research, 
results may continue to be mixed (2011). Furthermore, the lack of evidence for omega-3 found in 
this meta-analysis also adds to findings which have queried whether there is any support for the 
use of omega-3 supplementation. For example, controversial findings from a Cochrane review 
challenged a common acceptance that increased consumption of omega-3 can protect against 
heart disease, stroke or death, despite previous research finding a support (Von Schacky & 
Harris, 2007). The review found no support for the current recommendations for the use of 
omega-3 supplements in individuals with a history of coronary heart disease. An older review 
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also found a similar result (Hooper et.al, 2006). Non-significant findings are of equivalent 
importance than those that show an effect. Based on the current review, there is no evidence that 
omega-3 supplementation will be of benefit for reducing externalizing behaviours in typically 
developing children and adolescents.   
 
4.2 Limitations  
 Whilst many of the methodological limitations in trials included in this review 
have been discussed, it is important to also address the limitations in the design of this review. 
Firstly, a protocol was not registered for this analysis, whilst the Cochrane handbook 
recommends registering a protocol prior to conducting a review, this was not done and thus may 
increase the risk of reporting bias. Secondly, the electronic search was limited to published 
studies only which may increase publication bias. Clinical trials.gov and related websites were 
searched to address this limitation, as they include clinical trials registrations and ongoing trials. 
Examination of reference lists of the included studies and reviews were also conducted. 
Furthermore, this analysis, did not include fail-safe N statistics which is typically used to 
determine publication bias in a meta-analysis. The Cochrane handbook advises against the use of 
Fail-safe N statistics and as this analysis followed the requirements of a Cochrane review, these 
statistics were thus not included (Handbook). Moreover, the criteria of participants in this review 
excluded individuals with a neurodevelopmental or severe psychiatric disorder, which was 
identified by either a diagnosis or elevated levels on a subjective measure. Due to the 
overlapping of various symptoms and co-morbidity of externalizing behaviour disorders with 
ADHD, it is difficult to determine whether individuals with EB also would meet the criteria of a 
diagnosis of ADHD. This may limit the generalisability of results to a typically developing 
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population. This study also did not include analysis of subgroups, whilst planned analysis of 
differential effects of age, comparative analysis of supplementation type (i.e DHA vs EPA etc) 
and length of intervention was intended to be completed, due to the low number of trials in EB 
domains, this was not possible. Lastly, follow up-data was also not analysed, this could be 
considered a limitation in omega-3 research due to the optimum length of intervention effect 
being unknown.  
 
4.3 Strengths 
 The strengths in the design of this review include the separate analysis of parent, 
teacher and self-report data, this can been seen as a strength due to the subjective nature of 
outcome measures and the potential variability in responses across respondents. For example, 
parent report may been seen as superior to teacher ratings as they may be more sensitive to small 
changes (Kirby, Woodward, Jackson, Wang, & Crawford, 2010).  The analysis of RCT’s which 
included a placebo group can be considered a strength as this is the highest level of evidence to 
determine the evidence base of an intervention (see Centre for Evidence-Based Medicine, 2009) 
Furthermore, the adherence to the Cochrane handbook and PRISMA guidelines and the use of 
risk of bias analysis can also be considered a strength. For example, a previous meta-analysis on 
aggression (including externalizing behaviours combined) did not rate the quality of the studies 




 This review does not support nor refute the evidence for omega-3 
supplementation for reducing behaviour outcomes in typically developing children and 
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adolescents. Nonetheless, this review highlighted the methodological inconsistencies across trials 
in omega-3 research. More research is needed to determine the optimum quantity and length of 
dosage for an effect in a typically developing population. Further evidence from sufficiently 
powered trials with consistent methodologies is important to establish whether there is an 
evidence-based support for omega-3 supplementation for externalizing behaviour’s in typically 
developing children and adolescents. 
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Appendix B 
Example Data extraction sheet 
 
Data Extraction Form 
 
Review ID:  Study ID: Montgomery 2018 
 
Reference ID: Montgomery 2018 
 
Person extracting data  
(data should be extracted 
independently by at least 2 people): 
 
Date of date extraction: 
01/08/2018 
Year of study publication: 
2018 
Title: Docosahexaenoic acid for reading, working memory and behavior in UK children aged 7-9: A randomized 
controlled trial for replication (the DOLAB II study). 
 
Author: (Montgomery, Spreckelsen, Burton, Burton, & Richardson) 
 
Reference: Montgomery, P., Spreckelsen, T. F., Burton, A., Burton, J. R., & Richardson, A. J. (2018). 
Docosahexaenoic acid for reading, working memory and behavior in UK children aged 7-9: A randomized 
controlled trial for replication (the DOLAB II study). PloS one, 13(2), e0192909. 
Other publications from same study (additional reports of the same study should be grouped under the same 







Type of study design (e.g. parallel; cluster; cross-over trial) 
 
Parallel, randomized, double-blind placebo-controlled trial  
 
Participants and setting 
 
 
Describe setting:  Schools provided with a 16 week supply of capsules (labelled with each participating 
child’s name) to dispense 3 capsules to all participating children once a day at lunch time during school 
terms. Parents were also given a 16-week supply of capsules dispense to their children at weekends, 
school holidays and at any other time when their children were not in school. Primary outcomes were 
assessed at baseline for all children, and again at 16-week follow-up.  
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Inclusion criteria: Healthy Children aged 7-9 underperforming in reading – 20th percentile  
 
Exclusion criteria: Children with medical disorders, learning difficulties, medications which can effect 







Experimental intervention: Fixed dose of 600 mg DHA (from algal oil), three 500mg caps per day(200 
mg) each 




Control/Comparison intervention: Placebo – three, taste-and colour-matched 500 mg capsules per 
day containing corn/soybean oil 






Behaviour (Oppositional & hyperactivity ) - Conners’ Rating Scale (CPRS-L) – Parent  
Behaviour (Oppositional & hyperactivity ) - Conners’ Rating Scale (CTRS-L)- Teacher 
 
 
Risk of Bias assessment 
See Chapter 8 of the Cochrane Handbook. Additional domains may be added for non-randomised 
studies. 
Domain Risk of bias Support for judgement 
(include direct quotes where available 
with explanatory comments) 
Location in text 
or source (pg & 




   
Randomization was Independently 
performed by a statistician at Sealed 
Envelope Ltd with minimization via a 
1:1 allocation ratio.  “Algorithim 
ensured balanced allocation of 
participants between the treatment 
groups for each school (to allow for any 
sociodemographic/school differences) 
Page 7 











and sex of the child but also included a 




   








   
Active treatment and placebo were 
matched for taste and appearance. 
Investigators, participants and those 
assessing outcomes were all blind to 
treatment allocation. Blinding was 
assessed post intervention for teachers 
and parents  





   
Outcome group: Parent/teacher rated 
behaviour – Both parents and teachers 






   
Outcome group:  Parent rated 
behaviour(oppositional)- Post 
intervention 46/147 missing from 
intervention group, 45/156 missing 
from placebo. Intention to treat analysis 
used and analysis of attrition bias 
determined.  





   
Outcome group:  Teacher rated 
behaviour(oppositional)- Post 
intervention 6/136 missing from 
intervention group, 6/133 missing from 
placebo  Intention to treat analysis used 






   
All outcomes described in method are 
reported in results  
Page 10-20 
Other bias                
Notes:         
 






Outcomes for main analysis 
 
 
   
Outcome Measures 
(Continuous)    
      Total number of participants in study = 
 
Intervention group  
Total no. in group = 
Control group 
Total no. in group = 
mean SD        
 
total  mean SD       total 
 Primary        
1 Teacher rated Oppositional 
behaviour CRS 
54.2 10.9 187 53.8 10.1 189 
2 Parent rated   
Oppositional behaviour CRS 
53.6 8.8 187 53.3 8.7 189 
 Secondary       
4 Teacher ADHD 54.1 8.5 187 52.8 8.6 189 
5 Parent ADHD 54.3 8.9 187 53.1 9.2 189 
 
 
Outcomes for sub-group analyses 
 
   
Outcome Measures (Dichotomou 
    Total number of participants in study = 
 
Intervention group  
Total no. in group = 
Control group 
Total no. in group = 
events total events total 
      
1 Total – sex 376 M= 235 62.5% F = 141 37.5% 
2 Male 120 64.2 115 63.2 
3 Female 67 35.8 74 40.7 
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Outcome Measures (Continuous)    
      Total number of participants in study =376 
 
Intervention group  
Total no. in study = 
Control group 
Total no. in study = 
mean SD       total mean SD total 
 Primary       
1 Age = 105.5 (10.1)  105.6  10.2 187 105.3 10.1 189 
2 Free school meals = 78 (20.7) 33 17.6 187 45 24.7 189 
3        
        
        
        
                                 




Very brief summary of study authors main findings/conclusions: 
 
Replication study of DOLAB 1. Significant differences were not found for behaviour outcomes and 







This form was adapted from “Good practice templates” developed by the Cochrane 
Editorial Resources Committee 
http://training.cochrane.org/authors/presentations/collecting-data 
 
 
 
